close
close
HomeNews UpdateMerck & Co sees value in novel prostate cancer drug | Pharmaceuticals | The Pharmaletter

Merck & Co sees value in novel prostate cancer drug | Pharmaceuticals | The Pharmaletter

July 1, 2024
Merck & Co sees value in novel prostate cancer drug | Pharmaceuticals | The Pharmaletter

A joint development agreement between Finland’s Orion Corporation (HEL: ORNAV) and Merck & Co (NYSE: MRK) has been expanded to an exclusive worldwide license agreement.

The two companies are collaborating on the development of opevesostat, an experimental CYP11A1 inhibitor for the treatment of hormone-dependent cancers such as prostate cancer.

Liisa Hurme, President and CEO of Orion, emphasized the strategic benefits of the new agreement.

This article is available to registered users. To continue reading, please register for free. A free trial gives you one week’s access to exclusive features, interviews, summaries and commentary from the brightest minds in pharma and biotech. If you are already a registered user, please log in. If your trial has expired, you can log in here.

Log in to your account

Become a subscriber

820 €

Or £77 per month

Subscribe now

  • Unlimited access to industry-leading news, commentary and analysis from the pharmaceutical and biotechnology sectors.
  • News on clinical trials, conferences, mergers and acquisitions, licensing, financing, regulatory, patents and legal, executive appointments, business strategy and financial results.
  • Daily summary of the most important events in the pharmaceutical and biotechnology industry.
  • Monthly detailed briefings on board appointments and M&A news.
  • Choose between a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable service for the life sciences, providing a daily update on performance personnel and products. It is one of the most important pieces of information that keeps me informed

Chairman, Sanofi Aventis UK

Related Posts

About The Author

reggie